SGEN News and Press, Seagen Inc. From 12/04/23

2023-12-04 21:29:35 ET Summary Baker Brothers' 13F portfolio value increased marginally from $17.28B to $17.35B. The largest five stakes in the portfolio are Seagen, BeiGene, Incyte, ACADIA Pharma, and BioMarin Pharma, making up approximately 86% of the portfolio. Stake increa...

2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...

2023-11-30 17:44:52 ET More on Merck, Seattle Genetics, etc. Merck & Co., Inc. (MRK) Management Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript) Merck Will Keep Your Retirement Income Healthy Merck: Not The Time To Be Adding Amazon W...

FDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer PR Newswire – Results of pivotal confirmatory trial found...

2023-11-30 15:10:23 ET Summary AbbVie Inc. is set to acquire drug developer ImmunoGen, Inc. for $10.1 billion, diversifying its oncology pipeline and potentially transforming its cancer care business. ImmunoGen's antibody drug conjugate, Elahere, is approved to treat ovarian cance...

2023-11-30 07:42:10 ET More on AbbVie, ImmunoGen, etc. AbbVie: Collect Growing Passive Income From This Dividend Aristocrat (Rating Upgrade) Buy The Dip In AbbVie? Nope, Not This Time 4.5%-Yielding AbbVie Is One Of My Favorite Value Plays For 2024 AbbVie repo...

2023-11-28 11:12:14 ET More on Pfizer, Seattle Genetics, etc. Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips Pfizer Stock: Cheap But Will Remain Cheap, For Now Pfizer: Victim Of Vaccine Side Effects Pneumonia outbreak in China is no reason ...

2023-11-19 07:11:04 ET Summary Top merger stocks held by funds include Seagen and VMware, with pending deals expected to close soon. Market uncertainty surrounding the VMware merger has led to a perplexing stock price for its shares. Looking at the top holdings of arb hedge fu...

2023-11-15 12:30:18 ET Tudor Investment, the hedge fund founded by billionaire Paul Tudor Jones, started new positions in Seagen ( NASDAQ: SGEN ), with 340K shares, AbbVie ( NYSE: ABBV ), with 157.3K shares, and Verisk Analytics ( NASDAQ: VRSK ), with 80.2K shares, d...

2023-11-10 09:54:59 ET More on Seattle Genetics Seagen's Acquisition: EU Approval And Potential Upside Seagen Acquisition By Pfizer: A Strategic Power Move With Potential Windfalls For Investors Pfizer CEO expects Seagen deal to close before year end, or early in 202...